AACR logo

More articles from Large Molecule Therapeutics

Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages
Megan M. Cleary, Narendra Bharathy, Jinu Abraham, Erin R. Rudzinski, Joel E. Michalek, Charles Keller

Molecular Cancer Therapeutics Apr 2021, DOI: 10.1158/1535-7163.MCT-20-0199
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII
Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl, Grit Lorenczewski, Ines Ullrich, Markus Muenz, Benno Rattel, Julie M. Bailis, Matthias Friedrich

Molecular Cancer Therapeutics Feb 2021, DOI: 10.1158/1535-7163.MCT-20-0508
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer
Amy A. Lo, Jennifer Johnston, Ji Li, Danielle Mandikian, Maria Hristopoulos, Robyn Clark, Dorothee Nickles, Wei-Ching Liang, Kathy Hötzel, Debra Dunlap, Thinh Pham, Hao Cai, Meric Ovacik, Daniel Bravo-Perez, Elaine Mai, Dionysos Slaga, Diego Ellerman, James Ziai, Klara Totpal, Genee Lee, C. Andrew Boswell, Jian Payandeh, Yan Wu, Teemu T. Junttila

Molecular Cancer Therapeutics Apr 2021, 20 (4) 716-725; DOI: 10.1158/1535-7163.MCT-20-0490
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
William H. Gmeiner, Anthony Dominijanni, Alex O. Haber, Lais P. Ghiraldeli, David L. Caudell, Ralph D’Agostino, Boris C. Pasche, Thomas L. Smith, Zhiyong Deng, Sezgin Kiren, Chinnadurai Mani, Komaraiah Palle, Jonathan R. Brody

Molecular Cancer Therapeutics Mar 2021, 20 (3) 553-563; DOI: 10.1158/1535-7163.MCT-20-0516
ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium
Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan B. Gill, Douglas J. Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb, Richard Gorlick

Molecular Cancer Therapeutics Mar 2021, 20 (3) 535-540; DOI: 10.1158/1535-7163.MCT-20-0406
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D’Angelo, Andrew Garcia, Hong Chen, Allison M. Barrett, Sandrina Phipps, Ryan Fleming, Sonja Hess, Jens-Oliver Koopmann, Nazzareno Dimasi, Susan Wilson, Kathryn Pugh, Kimberly Cook, Luke A. Masterson, Changshou Gao, Herren Wu, Ronald Herbst, Philip W. Howard, David A. Tice, Mark Cobbold, Jay Harper

Molecular Cancer Therapeutics Mar 2021, 20 (3) 541-552; DOI: 10.1158/1535-7163.MCT-20-0351
Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12
Nuruddeen D. Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong Zi, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Adam Boutin, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doherty, Leonid Gaidukov, Scott Estes, Kyriakos D. Economides, Douglas E. Williams, Sriram Sathyanarayanan

Molecular Cancer Therapeutics Mar 2021, 20 (3) 523-534; DOI: 10.1158/1535-7163.MCT-20-0484
HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
Vianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, Anja Baumann, Nicola Giesen, Anikó Pálfi, Christoph Müller, Christian Lutz, Torsten Hechler, Michael Kulke, Carsten Müller-Tidow, Alwin Krämer, Hartmut Goldschmidt, Andreas Pahl, Marc S. Raab

Molecular Cancer Therapeutics Feb 2021, 20 (2) 367-378; DOI: 10.1158/1535-7163.MCT-20-0287
Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling
Arthur J. Van De Vyver, Tina Weinzierl, Miro J. Eigenmann, Nicolas Frances, Sylvia Herter, Regula B. Buser, Jitka Somandin, Sarah Diggelmann, Florian Limani, Thorsten Lehr, Marina Bacac, Antje-Christine Walz

Molecular Cancer Therapeutics Feb 2021, 20 (2) 357-366; DOI: 10.1158/1535-7163.MCT-20-0269
Development of Novel Antibody–Camptothecin Conjugates
Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter, Scott C. Jeffrey

Molecular Cancer Therapeutics Feb 2021, 20 (2) 329-339; DOI: 10.1158/1535-7163.MCT-20-0526

Main menu

User menu

Search

More articles from Large Molecule Therapeutics

Pages

Articles

Info for

About MCT